SMi鈥檚 16th annual Pain Therapeutics conference will hone in on the latest innovations and novel approaches to pain therapy and analgesic drugs as well as look at the practicalities of using animal models and translational biomarkers in pain research.
Aimed at an audience of senior specialists in neurology, CNS, clinical sciences and pharmacology, Pain Therapeutics 2016 will keep attendees at the forefront of scientific breakthroughs to adapt to the growing need towards minimising opioid dependency.
Understanding drug development mechanisms, neuropathic pain, severe chronic pain, sodium channels and industry challenges will be a major focus, as will hearing from a selection of leading pharmaceutical companies currently developing novel analgesic treatments. This will include presentations from Glenmark, Pfizer, GSK, Grunenthal, Nektar Pharmaceuticals and Novartis.
Interactive panel discussions on experimental clinical trials and alternative approaches to pain therapy will be just some of the highlights at the 16th annual show when it returns to London this spring.
Unrivalled Speaker Line-up Includes:
Steven Kamerling, Therapeutic Area Head for Pain and Inflammation, Zoetis
Stephen Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Pharmaceuticals
Shaloo Pandhi, Global Program Medical Director, Novartis
Neelima Khairatkar Joshi, Sr Vice President, Glenmark Pharmaceuticals
Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
Ozgur Sancak, Global Medical Science Lead 鈥� Pain, RB
Thomas Christoph, Senior Director, Head of Pain Pharmacology, Grunenthal
Chao Chen, Therapy Area Head, GSK
Catherine Stehman-Breen, VP Clinical Sciences, Regeneron
A detailed agenda and further information is available online at http://www.pain-therapeutics.co.uk
Visit the website for earlybird rates and to download a brochure.
Aimed at an audience of senior specialists in neurology, CNS, clinical sciences and pharmacology, Pain Therapeutics 2016 will keep attendees at the forefront of scientific breakthroughs to adapt to the growing need towards minimising opioid dependency.
Understanding drug development mechanisms, neuropathic pain, severe chronic pain, sodium channels and industry challenges will be a major focus, as will hearing from a selection of leading pharmaceutical companies currently developing novel analgesic treatments. This will include presentations from Glenmark, Pfizer, GSK, Grunenthal, Nektar Pharmaceuticals and Novartis.
Interactive panel discussions on experimental clinical trials and alternative approaches to pain therapy will be just some of the highlights at the 16th annual show when it returns to London this spring.
Unrivalled Speaker Line-up Includes:
Steven Kamerling, Therapeutic Area Head for Pain and Inflammation, Zoetis
Stephen Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Pharmaceuticals
Shaloo Pandhi, Global Program Medical Director, Novartis
Neelima Khairatkar Joshi, Sr Vice President, Glenmark Pharmaceuticals
Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
Ozgur Sancak, Global Medical Science Lead 鈥� Pain, RB
Thomas Christoph, Senior Director, Head of Pain Pharmacology, Grunenthal
Chao Chen, Therapy Area Head, GSK
Catherine Stehman-Breen, VP Clinical Sciences, Regeneron
A detailed agenda and further information is available online at http://www.pain-therapeutics.co.uk
Visit the website for earlybird rates and to download a brochure.
